Drugs / Human immune globulin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00547365 | Oct 2007 → Jul 2011 | plasma cell myeloma | University of Tennessee | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07635511 Background | Jun 2026 → Jan 2029 expected | anti-HLA hyperimmunization, hematopoietic and lymphoid cell neoplasm, platelet disorder, undefined | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human immune globulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07635511 ↗ |
| Known as | IGIV | “Human immune globulin intravenous (IGIV)” NCT00547365 ↗ |
| Route | Intravenous | “Patients receive human immune globulin IV (IGIV) once weekly for 3 months and then once biweekly for 9 months” NCT00547365 ↗ |